Intra-cellular therapies announces publications highlighting beneficial effects of phosphodiesterase type i inhibition with lenrispodun (iti-214) on cardiovascular function in patients with heart failure and in models of accelerated aging

Results of study iti-214-104 show that lenrispodun, in a phase 1/2a study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms (circulation: heart failure; gilotra, et al, 2021)
ITCI Ratings Summary
ITCI Quant Ranking